| 1.24 -0.01 (-0.8%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.69 | 1-year : | 1.85 |
| Resists | First : | 1.44 | Second : | 1.59 |
| Pivot price | 1.4  |
|||
| Supports | First : | 1.22 | Second : | 1.01 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.42 |
| MA(100) : | 1.44 |
MA(250) : | 1.32  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 9.5 |
| RSI | RSI(14): 26.9 |
|||
| 52-week | High : | 2.45 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MIRA ] has closed below the lower bollinger band by 0.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 10.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.29 - 1.3 | 1.3 - 1.31 |
| Low: | 1.21 - 1.22 | 1.22 - 1.23 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Fri, 05 Dec 2025
MIRA Pharmaceuticals Increases Stock Offering Limit - TradingView
Fri, 05 Dec 2025
Mira Pharmaceuticals increases at-the-market offering by $15.2 million - Investing.com
Thu, 16 Oct 2025
MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data - Benzinga
Thu, 16 Oct 2025
Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making - Stocktwits
Thu, 16 Oct 2025
$70.3B Market: MIRA's Oral Mira-55 Normalized Pain, Cut Inflammation; Supports IND - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 42 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 16.6 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 389 (K) |
| Shares Short P.Month | 274 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.7 % |
| Return on Equity (ttm) | -123.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 6.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|